Advertisement

Agents and Actions

, Volume 25, Issue 1–2, pp 191–194 | Cite as

Failure of PAF-acether to inducein vivo neutrophil migration

  • F. Q. Cunha
  • N. E. Heluy-Neto
  • A. Klein
  • G. E. P. Souza
  • S. H. Ferreira
Platelets and Thrombosis
  • 13 Downloads

Abstract

The ability of PAF-acether (platelet activating factor, 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to induce neutrophil migration was tested in the peritoneal cavities of rats and guinea-pigs and in rat skin air pouches. PAF-acether, at doses of 2 and 5 μg per animal, did not promote significant neutrophil migration. The ability of PAF-acether antagonists to inhibit carrageenin induced neutrophil migration in rat abdominal cavities was also investigated. Carrageenin is a substance described to cause the release of endogenous PAF-acether. Neutrophil migration was not affected by PAF-antagonists. These observations challenge the possible role of PAF-acether as a neutrophil chemotactic factorin vivo.

Keywords

Peritoneal Cavity Abdominal Cavity Activate Factor Platelet Activate Platelet Activate Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    P. Braquet, L. Touqui, T. Y. Shen and B. B. Vargaftig,Perspectives in Platelet-activating factor research. Pharm. Rev.39, 97–145 (1987).PubMedGoogle Scholar
  2. [2]
    R. S. B. Cordeiro, M. A. Martim, P. M. R. e Silva, H. C. Castro Faria Neto, J. R. C. Castanheira and B. B. Vargaftig,Desensitization to PAF-induced rat paw oedema by repeated intraplantar injections. Life Sci.39, 1871–1878 (1986).CrossRefPubMedGoogle Scholar
  3. [3]
    B. B. Vargaftig and S. H. Ferreira,Blockade of the inflammatory effects of platelet activating factor by cyclo-oxygenase inhibitors. Braz. J. Med. Biol. Res.14, 187–189 (1981).PubMedGoogle Scholar
  4. [4]
    J. O. Shaw, R. N. Pinckard, K. S. Ferrigni, L. M. Mcmanus and D. J. Hanahan,Activation of human neutrophils with 1.0 hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J. Immunol.127, 1250–1255 (1981).PubMedGoogle Scholar
  5. [5]
    A. J. Wardlaw, M. R. C. P. Wardlaw and A. B. Kay,PAF-acether is a potent chemotactic factor for human eosinophils. J. of Allergy and Clinical Immunol77 (supl), 236 (1986).Google Scholar
  6. [6]
    B. M. Czarnetzki and J. Benveniste,Effect of synthetic PAF-acether on human neutrophil function. Les colloques de l'Inserm Pharmacology of inflammation and Allergy. (Eds. F. Russo Marie, B. B. Vergaftig and J. Benveniste). INSERM100, 105–109 (1981).Google Scholar
  7. [7]
    D. M. Humphrey, R. N. Pinckard, L. M. Mcmanus and D. J. Hanahan,Intradermal neutrophil infiltrates induced by 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholyne (AGEPC). Fed. Proceedings40, 1003 (1981).Google Scholar
  8. [8]
    D. M. Humphrey, D. J. Hanahan and R. N. Pinckard,Induction of leukocytic infiltrates in rabbit skin by acetyl-glyceryl-ether-phosphorylcholine. Lab. Invest.47, 227–234 (1982).PubMedGoogle Scholar
  9. [9]
    I. G. Colditz and H. Z. Movat,Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. J. Immunol.133, 2163–2168 (1984).PubMedGoogle Scholar
  10. [10]
    I. G. Colditz and H. Z. Movat,Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. J. Immunol.133, 2169–2173 (1984).PubMedGoogle Scholar
  11. [11]
    P. M. R. Silva, R. S. B. Cordeiro, M. A. Martins, M. G. M. O. Henriques and B. B. Vargaftig,Platelet involvement in rat paw edema induced by 2-methoxy-PAF. Inflammation10, 393–401 (1986).CrossRefPubMedGoogle Scholar
  12. [12]
    M. Di Rosa, J. P. Giroud and D. A. Willoughby,Studies of the mediators of the acute inflammatory response induced in rats in different sites carragenan and turpentine. J. Path.104, 15–29 (1971).CrossRefPubMedGoogle Scholar
  13. [13]
    C. V. Wedmore and T. J. Williams,Control of vascular permeability by polymorphonuclear leucocytes in inflammation. Nature289, 646–650 (1981).CrossRefPubMedGoogle Scholar
  14. [14]
    J. C. W. Edwards, A. D. Sedwick and D. A. Willoughby,The formation of a structure with the features of synovial lining by subcutaneous injection of air. An “in vivo” tissue culture system. J. Path.134, 147–153 (1981).CrossRefPubMedGoogle Scholar
  15. [15]
    G. E. P. Souza and S. H. Ferreira,Blockade by antimacrophage serum of the migration of PMN neutrophils into the inflamed peritoneal cavity. Agents and Actions17, 97–103 (1985).CrossRefPubMedGoogle Scholar
  16. [16]
    B. B. Lorenzetti, G. E. P. Souza, F. Q. Cunha and S. H. Ferreira,Anti-inflammatory effects of BN-52021. Proc. of 2nd Symposium “There is a Case for PAF-Acether Antagonists”. Paris, 1988.Google Scholar
  17. [17]
    A. W. Ford-Hutchinson, G. Brunet, P. Savard and S. Charleson,Leukotriene B4, polymorphonuclear leukocytes and inflammatory exudates in the rat. Prostaglandins28, 13–27 (1984).CrossRefPubMedGoogle Scholar
  18. [18]
    M. J. H. Smith, A. W. Ford-Hutchinson and M. A. Bray,Leukotriene B: a potential mediator of inflammation. J. Pharm. Pharmacol.32, 517–518 (1980).PubMedGoogle Scholar
  19. [19]
    F. Q. Cunha and S. H. Ferreira,The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: inhibition by glucocorticoids. Eur. J. Pharmacol.129, 65–76 (1986).CrossRefPubMedGoogle Scholar
  20. [20]
    P. C. Wilkinson,Cellular accumulation and inflammation. InTextbook of Immunopharmacology (Ed. M. M. Dale and J. C. Foreman) pp. 217–232. Blackwell Scientific Publications, Oxford 1984.Google Scholar
  21. [21]
    L. Parente and R. J. Flower,The generation of lyso-PAF in experimental inflammation. InInflammatory Mediators (Ed. G. A. Higgs and T. J. Williams), pp. 65–71. Macmillan Press, London 1985.Google Scholar
  22. [22]
    R. S. B. Cordeiro, P. M. R. Silva, M. A. Martins and B. B. Vargaftig,Salicylates inhibit PAF-acether-induced rat paw oedema when cyclooxigenase inhibitors are ineffective. Prostaglandins32, 719–727 (1986).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • F. Q. Cunha
    • 1
    • 2
  • N. E. Heluy-Neto
    • 1
    • 2
  • A. Klein
    • 1
    • 2
  • G. E. P. Souza
    • 1
    • 2
  • S. H. Ferreira
    • 1
    • 2
  1. 1.Department of Pharmacology of the Faculty of MedicineUniversity of São PauloRibeirão PretoBrazil
  2. 2.the Faculty of Pharmaceutical Sciences of Ribeirão PretoUniversity of São PauloRibeirão PretoBrazil

Personalised recommendations